

August 9, 2022

Dear Representative:

On behalf of the Endocrine Society, the world's largest professional organization of endocrinologists, I am writing to urge your support of the *Inflation Reduction Act*, which will make insulin more affordable for people with Medicare. We urge you to pass this bill and send it to the President without delay. Endocrine Society members provide care to millions of people across the country with diabetes who rely on insulin to live. This legislation is an important step in addressing insulin affordability.

Last year was the 100th anniversary of the discovery of insulin, and despite this important milestone, insulin remains unaffordable for many who rely on it. The price of insulin nearly tripled between 2002 and 2013. More recently, the list price of insulin nearly doubled between 2012 and 2016. In the United States, more than 7 million people rely on insulin to manage their diabetes to live. People who rely on insulin have struggled to afford this medication for many years, but the impacts of inflation have made this issue even more dire due to the rising cost of basic necessities. People with diabetes should not be forced to choose between buying groceries and taking the medication they need to survive.

The Endocrine Society previously shared with the House [patient stories](#) from around the country illustrating that people with diabetes continue to suffer due to the high price of insulin. We have also offered a spectrum of [policy recommendations](#) to make insulin more affordable. We are pleased that the *Inflation Reduction Act* would institute a \$35 co-pay cap on out-of-pocket costs of insulin for Medicare beneficiaries and allow Medicare to negotiate the price of a defined number of prescription drugs. These provisions align with the Society's policy recommendations on insulin access and affordability and would provide meaningful relief to Medicare beneficiaries who rely on insulin. It's time for Congress to address this longstanding problem and pass this legislation today. **On behalf of our patients, we urge you to support passage of the Inflation Reduction Act because we cannot lose this opportunity to finally begin to address insulin affordability.**

If you have any questions or we can be of any further assistance, please have your staff contact the Endocrine Society's director of advocacy and policy, Rob Goldsmith, at rgoldsmith@endocrine.org.

Sincerely,



Ursula Kaiser, MD
President
Endocrine Society